Morgan Stanley
NEPH icon

Morgan Stanley’s Nephros NEPH Stock Holding History

Morgan Stanley’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$460K Sell
123,915
-5,000
-4% -$20K ﹤0.01% 5648
2026
Q2 		$460K Buy
128,915
+18,000
+16% +$58.5K ﹤0.01% 5591
2026
Q1 		$331K Buy
110,915
+92,956
+518% +$371K ﹤0.01% 5673
2025
Q4 		$87.6K Buy
17,959
+16,044
+838% +$82K ﹤0.01% 6254
2025
Q3 		$9.06K Hold
1,915
– – ﹤0.01% 6928
2025
Q2 		$7.83K Sell
1,915
-3,508
-65% -$9.37K ﹤0.01% 6921
2025
Q1 		$9.33K Hold
5,423
– – ﹤0.01% 6823
2024
Q4 		$7.97K Hold
5,423
– – ﹤0.01% 6880
2024
Q3 		$9.27K Hold
5,423
– – ﹤0.01% 6739
2024
Q2 		$11.4K Hold
5,423
– – ﹤0.01% 6630
2024
Q1 		$11.9K Sell
5,423
-28,351
-84% -$89.9K ﹤0.01% 6648
2023
Q4 		$117K Buy
33,774
+18,482
+121% +$40.2K ﹤0.01% 5884
2023
Q3 		$22.6K Hold
15,292
– – ﹤0.01% 6440
2023
Q2 		$23.7K Hold
15,292
– – ﹤0.01% 6512
2023
Q1 		$16.4K Hold
15,292
– – ﹤0.01% 6695
2022
Q4 		$17.7K Hold
15,292
– – ﹤0.01% 6733
2022
Q3 		$14K Sell
15,292
-2,962
-16% -$4.19K ﹤0.01% 6953
2022
Q2 		$28K Buy
18,254
+10,729
+143% +$29K ﹤0.01% 6854
2022
Q1 		$33K Buy
7,525
+1,049
+16% +$4.98K ﹤0.01% 6902
2021
Q4 		$38K Sell
6,476
-7,361
-53% -$53.7K ﹤0.01% 6933
2021
Q3 		$121K Buy
13,837
+9,004
+186% +$78.1K ﹤0.01% 6264
2021
Q2 		$49K Buy
4,833
+1,018
+27% +$8.49K ﹤0.01% 6685
2021
Q1 		$25K Hold
3,815
– – ﹤0.01% 6646
2020
Q4 		$33K Hold
3,815
– – ﹤0.01% 6289
2020
Q3 		$28K Hold
3,815
– – ﹤0.01% 5935
2020
Q2 		$32K Hold
3,815
– – ﹤0.01% 5849
2020
Q1 		$24K Buy
+3,815
New +$32.4K ﹤0.01% 5743

Other funds holding NEPH

Massachusetts Institute of Technology
Massachusetts Institute of Technology Cambridge, Massachusetts $695M AUM 43.77% 1-Year Est. Return
Wexford Capital
Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Meritage Group
Meritage Group San Francisco, California $2.78B AUM 9.1% 1-Year Est. Return
Bard Associates
Bard Associates Chicago, Illinois $431M AUM 30.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Mesirow Financial Investment Management
Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Morgan Stanley's NEPH Position: Q3 2026 in Review

Morgan Stanley reduced its Nephros (NEPH) stake by 3.9% in Q3 2026, selling an estimated $20K and leaving 123,915 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #5648.

Morgan Stanley first reported a position in NEPH in Q1 2020 and has held it in 27 quarters since. The position peaked at $460K in Q2 2026. 26 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

  • Morgan Stanley held 123,915 shares of Nephros worth $460K as of Q3 2026.
  • Morgan Stanley sold 5,000 Nephros shares in Q3 2026, an estimated $20K.
  • Nephros made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #5648 holding.
  • Morgan Stanley first reported a position in Nephros in Q1 2020 and has held it in 27 quarters since.
  • Morgan Stanley's Nephros position peaked at $460K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.